Phase 3 N=11 A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Participants With >/= 95 % Bruton's Tyrosine Kinase (BTK) Occupancy — 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=269 Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate
Rheumatoid Arthritis
Primary: Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12 — -13.87; -21.71; -22.83; -24.77 units on a scale — p=0.0050
Phase 3 N=40 Blood Loss Reduction After Total Knee Arthroplasty. Comparison Topical Tranexamic Acid vs Platelet Rich Plasma
Osteoarthritis
Primary: Therapeutic Effect on Hemoglobin Level — 13.6; 13.6; 10.3; 9.9 g/dL
Phase 2 N=44 OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO
Accidental Falls · Fall Due to Loss of Equilibrium · High Risk of Falls Due to Mobility Limitation
Primary: Hip Sway Change From Baseline to 6 Months — 3.65; 3.75; 2.15; 3.89 degree^2 — p=0.040
Phase 4 N=10 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
Autism Spectrum Disorder · Asperger Syndrome · Aspergers Syndrome
Primary: Change in Score on Conners Adults Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale — 68.6; 71.8; 53.4; 57 T-score
Phase 4 N=38 Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
Systemic Lupus Erythematosus (SLE)
Primary: Number of Participants Who Meet the Definition of a Responder Within 4 Weeks — 3; 4 Participants
Phase 3 N=3,183 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial…
N/A N=19 Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Autism Spectrum Disorders
Primary: Number of Participants With Improvement on the Clinical Global Impression-Improvement (CGI-I) Scale — 3; 1 Participants
Phase 2 N=30 Micro-mobile Foot Compression and Diabetic Foot
Diabetes · PAD · Lower Extremity Edema
Primary: Change in Balance From Baseline to 4 Weeks — 0.94; 0.76 cm
Phase 3 N=323 Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
Charcot-Marie-Tooth Disease Type 1A
Primary: Overall Neuropathy Limitation Scale (ONLS) Total Score — 3.33; 3.05; 3.23; 3.25 Scores on the ONLS — p=0.008
N/A N=48 Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
N/A N=34 Heat Acclimation, Hand Cooling Efficacy, and Adaptation Maintenance.
Heat
Primary: Internal Body Temperature — 39.6; 38.2 degrees Celcius
Phase 2 N=31 Red Blood Cell ATP Release and Vascular Function in Humans
Cardiovascular Diseases
Primary: Forearm Blood Flow Responses to Hypoxia After Administration of Intervention — 6.3; 6.2; 2.1; 8.4 mL/min — p=0.97
Phase 2 N=60 Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
Genitourinary Cancer · Kidney Cancer
Primary: Rate of Toxicity — 15; 8; 5; 3 Participants
Phase 3 N=859 Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
Community Acquired Bacterial Pneumonia
Primary: Early Clinical Response — 383; 381 Participants